Gossamer Bio is a startup based in All, most recent round IPO, 2 tracked investors.
Gossamer Bio is a company headquartered in All. Its most recent tracked round is IPO. Brouky records 2 investors associated with the company.
Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.